148 related articles for article (PubMed ID: 33662537)
1. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.
Lee JY; Shin YS; Jeon S; Lee SI; Noh S; Cho JE; Jang MS; Kim S; Song JH; Kim HR; Park CM
Bioorg Med Chem Lett; 2021 May; 39():127885. PubMed ID: 33662537
[TBL] [Abstract][Full Text] [Related]
2. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
3. Identification of 4-anilino-6-aminoquinazoline derivatives as potential MERS-CoV inhibitors.
Lee JY; Shin YS; Lee J; Kwon S; Jin YH; Jang MS; Kim S; Song JH; Kim HR; Park CM
Bioorg Med Chem Lett; 2020 Oct; 30(20):127472. PubMed ID: 32781216
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Scroggs SLP; Offerdahl DK; Flather DP; Morris CN; Kendall BL; Broeckel RM; Beare PA; Bloom ME
Viruses; 2020 Dec; 13(1):. PubMed ID: 33374514
[TBL] [Abstract][Full Text] [Related]
5. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 3-acyl-2-phenylamino-1,4-dihydroquinolin-4(1H)-one derivatives as potential MERS-CoV inhibitors.
Yoon JH; Lee JY; Lee J; Shin YS; Jeon S; Kim DE; Min JS; Song JH; Kim S; Kwon S; Jin YH; Jang MS; Kim HR; Park CM
Bioorg Med Chem Lett; 2019 Dec; 29(23):126727. PubMed ID: 31624041
[TBL] [Abstract][Full Text] [Related]
7. Valinomycin as a potential antiviral agent against coronaviruses: A review.
Zhang D; Ma Z; Chen H; Lu Y; Chen X
Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
[TBL] [Abstract][Full Text] [Related]
8. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
9. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
Ko M; Chang SY; Byun SY; Ianevski A; Choi I; Pham Hung d'Alexandry d'Orengiani AL; Ravlo E; Wang W; Bjørås M; Kainov DE; Shum D; Min JY; Windisch MP
Viruses; 2021 Apr; 13(4):. PubMed ID: 33918958
[TBL] [Abstract][Full Text] [Related]
10. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic.
Negi M; Chawla PA; Faruk A; Chawla V
Bioorg Chem; 2020 Nov; 104():104315. PubMed ID: 33007742
[TBL] [Abstract][Full Text] [Related]
11. Novel SARS-CoV-2 entry inhibitors, 2-anilinoquinazolin-4(3H)-one derivatives, show potency as SARS-CoV-2 antivirals in a human ACE2 transgenic mouse model.
Ko M; Lee JY; Shin YS; Jeon S; Myung S; Cho JE; Jang MS; Song JH; Kim HR; Park HG; Park CM; Kim S
J Med Virol; 2023 Jun; 95(6):e28863. PubMed ID: 37310127
[TBL] [Abstract][Full Text] [Related]
12. Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.
Shin YS; Lee JY; Noh S; Kwak Y; Jeon S; Kwon S; Jin YH; Jang MS; Kim S; Song JH; Kim HR; Park CM
Bioorg Med Chem Lett; 2021 Jan; 31():127667. PubMed ID: 33160024
[TBL] [Abstract][Full Text] [Related]
13. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
14. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
16. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
[TBL] [Abstract][Full Text] [Related]
18. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) coinfection: A unique case series.
Elhazmi A; Al-Tawfiq JA; Sallam H; Al-Omari A; Alhumaid S; Mady A; Al Mutair A
Travel Med Infect Dis; 2021; 41():102026. PubMed ID: 33727175
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors.
Zaher NH; Mostafa MI; Altaher AY
Acta Pharm; 2020 Jun; 70(2):145-159. PubMed ID: 31955138
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
